From Wikipedia, the free encyclopedia
Jump to: navigation, search

Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers.[1] Hence, anti-IL6 agents have been sought.[2][3][4][5][6]

The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor.[7] The second, siltuximab (Sylvant), is directed against IL-6 itself.[1][8]

Several agents are in clinical trials: sarilumab,[9] olokizumab (CDP6038)[10][11] elsilimomab, ALD518/BMS-945429, sirukumab (CNTO 136), and CPSI-2364 an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway.[12]

Agents in pre-clinical development include ARGX-109,[13][14] FE301,[1] FM101[15]


New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a myokine. IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage.[16] However, it has become evident that eccentric exercises are not associated with a larger increase in plasma IL-6 than exercise involving concentric “nondamaging” muscle contractions. This finding demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. In fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery.[17]

Anti-IL-6 therapies should therefore take into consideration the (beneficial) anti-inflammatory effects of myokines generally, including the now-established multiple benefits of muscle-derived Interleukin 6.[18]

Food and diet[edit]

It has been reported that lunasin, a soy peptide, reduces inflammation by reducing interleukin 6 and may help in leukemia[vague].[19]

Luteolin reduces IL-6 production in some neurons.[20]


  1. ^ a b c Jones SA, Scheller J, Rose-John S (2011). "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling". J. Clin. Invest. 121 (9): 3375–83. doi:10.1172/JCI57158. PMC 3163962. PMID 21881215. 
  2. ^ Barton BE (August 2005). "Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes". Expert Opin. Ther. Targets 9 (4): 737–52. doi:10.1517/14728222.9.4.737. PMID 16083340. 
  3. ^ Smolen JS, Maini RN (2006). "Interleukin-6: a new therapeutic target". Arthritis Res. Ther. 8 Suppl 2: S5. doi:10.1186/ar1969. PMC 3226077. PMID 16899109. 
  4. ^ Stein and Sutherland (1998). "IL-6 as a drug discovery target". Drug Discovery Today 3 (5): 202–213. doi:10.1016/S1359-6446(97)01164-1. 
  5. ^ "Interleukin-6 - new target in the battle against Ras-induced cancers". 2007. 
  6. ^ "Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis". 2003. 
  7. ^ Schoels MM, van der Heijde D, Breedveld FC et al. (2013). "Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement". Ann. Rheum. Dis. 72 (4): 583–9. doi:10.1136/annrheumdis-2012-202470. PMC 3595140. PMID 23144446. 
  8. ^
  9. ^
  10. ^ "UCB Announces Start Of Phase I Study For Antibody Drug Candidate CDP6038". 2 Dec 2008. 
  11. ^
  12. ^ PMID: 23598944
  13. ^ "ArGEN-X Wins €1.5M IWT Grant to Progress Camelid-Derived Human Antibody Pipeline". 27 Sep 2010. 
  14. ^
  15. ^ "Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals’ FM101 Monoclonal Antibody under Its "Fillanthrop". 30 July 2010. 
  16. ^ Bruunsgaard H, Galbo H, Halkjaer-Kristensen J, Johansen TL, MacLean DA, Pedersen BK. Exercise-induced increase in interleukin-6 is related to muscle damage. J Physiol Lond 499: 833-841, 1997.
  17. ^ Muscle as a secretory organ. Pedersen BK. American Physiological Society. Compr Physiol 3:1337-1362, 2013.
  18. ^ Muscle as a secretory organ. Pedersen BK Compr Physiol 2013; 3(3): 1337-62
  19. ^
  20. ^ Johnson; Kelley, KW; Johnson, RW et al. (May 2008). "Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 — PNAS". Proceedings of the National Academy of Sciences of the United States of America 105 (21): 7534–9. doi:10.1073/pnas.0802865105. PMC 2396685. PMID 18490655.